7. Hivatkozások
7.2. Irodalmi hivatkozások
(A hivatkozások között csillaggal jeleztem a saját közleményeket.)
Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de Córdoba SR, Sánchez-Corral P. 2009. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood. 114(19):4261-71.
* Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Józsi M, Zipfel PF, Hageman GS, Smith RJ. 2006. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet.
43(7):582-9.
Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF Jr. 2010.
Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res. 16(12):3226-31.
Ault BH, Schmidt BZ, Fowler NL, Kashtan CE, Ahmed AE, Vogt BA, Colten HR. 1997.
Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem. 272(40):25168-75.
Banda NK, Mehta G, Ferreira VP, Cortes C, Pickering MC, Pangburn MK, Arend WP, Holers VM. 2013. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol. 190(7):3560-9.
Blanc C, Roumenina LT, Ashraf Y, Hyvärinen S, Sethi SK, Ranchin B, Niaudet P, Loirat C, Gulati A, Bagga A, Fridman WH, Sautès-Fridman C, Jokiranta TS, Frémeaux-Bacchi V, Dragon-Durey MA. 2012. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol.
189(7):3528-37.
Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA. 2015. Anti-factor H
autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 194(11):5129-38.
Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrín D, Stehle T. 2015. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol. 11(1):77-82.
Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. 2009. The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol. 46(8-9):1573-94.
Caesar JJ, Lavender H, Ward PN, Exley RM, Eaton J, Chittock E, Malik TH, Goiecoechea De Jorge E, Pickering MC, Tang CM, Lea SM. 2014. Competition between antagonistic
complement factors for a single protein on N. meningitidis rules disease susceptibility. Elife.
2014 Dec 23;3.
Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E, Gamba S, Skerka C, Marziliano N, Remuzzi G, Noris M; Itaslian Registry of Familial and Recurrent HUS/TTP. 2001. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol. 12(2):297-307.
Chen Q, Manzke M, Hartmann A, Büttner M, Amann K, Pauly D, Wiesener M, Skerka C, Zipfel PF. 2016. Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces. J Am Soc Nephrol. 27(5):1413-25.
Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. 2014. Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane:
implications for age-related macular degeneration. J Immunol. 193(10):4962-70.
Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B. 2014.
Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Pediatrics. 133(6):e1764-8.
Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V. 2005. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 16(2):555-63.
Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, Fridman WH, Frémeaux-Bacchi V. 2009. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet. 46(7):447-50.
Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V.
2010. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.
J Am Soc Nephrol. 21(12):2180-7.
Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. 2005.
Complement factor H polymorphism and age-related macular degeneration. Science.
308(5720):421-4.
Erdei A. (szerk.) Immunológiai módszerek (Medicina, 2006; ISBN: 963 242 892 7).
Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. 2006. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol. 177(9):6308-16.
Ferreira VP, Herbert AP, Cortés C, McKee KA, Blaum BS, Esswein ST, Uhrín D, Barlow PN, Pangburn MK, Kavanagh D. 2009. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol.
182(11):7009-18.
Ferreira VP, Pangburn MK, Cortés C. 2010. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol. 47(13):2187-97.
Foltyn Zadura A, Zipfel PF, Bokarewa MI, Sturfelt G, Jönsen A, Nilsson SC, Hillarp A, Saxne T, Trouw LA, Blom AM. 2012. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther. 14(4):R185.
Foltyn Zadura A, Memon AA, Stojanovich L, Perricone C, Conti F, Valesini G, Bogdanovic G, Hillarp A, Shoenfeld Y, Sundquist J, Leffler J, Svensson PJ, Trouw LA, Blom AM. 2015.
Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis. J Rheumatol. 42(10):1786-93.
Forneris F, Wu J, Xue X, Ricklin D, Lin Z, Sfyroera G, Tzekou A, Volokhina E, Granneman JC, Hauhart R, Bertram P, Liszewski MK, Atkinson JP, Lambris JD, Gros P. 2016.
Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J. 35(10):1133-49.
Friese MA, Hellwage J, Jokiranta TS, Meri S, Peter HH, Eibel H, Zipfel PF. 1999. FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol. 36(13-14):809-18.
Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Frémeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC. 2010. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.
Lancet. 376(9743):794-801.
Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, Hakobyan S, Morgan BP, Harris CL, Pickering MC, Lea SM. 2013. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A.
110(12):4685-90.
Goodship TH, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ. 2012. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol. 52(3-4):200-6.
Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM. 1995. Identification of complement regulatory domains in human factor H. J Immunol. 155(1):348-56.
Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R. 2005. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 102(20):7227-32.
Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA.
2005. Complement factor H variant increases the risk of age-related macular degeneration.
Science. 308(5720):419-21.
* Heinen S, Józsi M, Hartmann A, Noris M, Remuzzi G, Skerka C, Zipfel PF. 2007.
Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. J Am Soc Nephrol. 18(2):506-14.
Heinen S, Hartmann A, Lauer N, Wiehl U, Dahse HM, Schirmer S, Gropp K, Enghardt T, Wallich R, Hälbich S, Mihlan M, Schlötzer-Schrehardt U, Zipfel PF, Skerka C. 2009. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood. 114(12):2439-47.
Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S, Zipfel PF. 1999. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 462(3):345-52.
* Hellwage J, Eberle F, Babuke T, Seeberger H, Richter H, Kunert A, Härtl A, Zipfel PF, Jokiranta TS, Józsi M. 2006. Two factor H-related proteins from the mouse: expression analysis and functional characterization. Immunogenetics. 58(11):883-93.
Høgåsen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M. 1995. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest. 95(3):1054-61.
Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T; German-Austrian HUS Study Group. 2013. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 8(3):407-15.
* Hofer J, Giner T, Józsi M. 2014. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Semin Thromb Hemost.
40(4):431-43.
Holmes LV, Strain L, Staniforth SJ, Moore I, Marchbank K, Kavanagh D, Goodship JA, Cordell HJ, Goodship TH. 2013. Determining the population frequency of the
CFHR3/CFHR1 deletion at 1q32. PLoS One. 8(4):e60352.
Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S. 1999. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 163(8):4590-6.
* Jokiranta TS, Cheng ZZ, Seeberger H, Józsi M, Heinen S, Noris M, Remuzzi G, Ormsby R, Gordon DL, Meri S, Hellwage J, Zipfel PF. 2005. Binding of complement factor H to
endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol. 167(4):1173-81.
Jokiranta TS, Jaakola VP, Lehtinen MJ, Pärepalo M, Meri S, Goldman A. 2006. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J. 25(8):1784-94.
* Józsi M, Reuter S, Nozal P, López-Trascasa M, Sánchez-Corral P, Prohászka Z, Uzonyi B.
2014. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunol Lett. 160(2):163-71.
Kajander T, Lehtinen MJ, Hyvärinen S, Bhattacharjee A, Leung E, Isenman DE, Meri S, Goldman A, Jokiranta TS. 2011. Dual interaction of factor H with C3d and
glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A. 108(7):2897-902.
Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. 2005. Complement factor H polymorphism in age-related macular degeneration. Science. 308(5720):385-9.
* Kopp A, Hebecker M, Svobodová E, Józsi M. 2012. Factor H: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules. 2(1):46-75.
Krushkal J, Bat O, Gigli I. 2000. Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol Biol Evol. 17(11):1718-30.
Kühn S, Skerka C, Zipfel PF. 1995. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H. J Immunol. 155(12):5663-70.
Kühn S, Zipfel PF. 1995. The baculovirus expression vector pBSV-8His directs secretion of histidine-tagged proteins. Gene. 162: 225–229.
Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS. 2009. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem. 284(23):15650-8.
* Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. 2006. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int.
70(1):42-50.
Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD, Ricklin D. 2015.
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood. 126(7):891-4.
* Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Józsi M, Neumann HP, Remuzzi G, Zipfel PF. 2003. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest.
111(8):1181-90.
McRae JL, Duthy TG, Griggs KM, Ormsby RJ, Cowan PJ, Cromer BA, McKinstry WJ, Parker MW, Murphy BF, Gordon DL. 2005. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol. 174(10):6250-6.
Meri S, Koistinen V, Miettinen A, Törnroth T, Seppälä IJ. 1992. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med. 175(4):939-50.
* Mihlan M, Stippa S, Józsi M, Zipfel PF. 2009. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 16(12):1630-40.
Monteferrante G, Brioschi S, Caprioli J, Pianetti G, Bettinaglio P, Bresin E, Remuzzi G, Noris M. 2007. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol Immunol. 44(7):1704-8.
Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ. 2010.
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
Blood. 115(2):379-87.
Morgan BP, Harris CL. 2015. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 14(12):857-77.
Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ.
2015. Atypical aHUS: State of the art. Mol Immunol. 67(1):31-42.
Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF. 2003. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet. 40(9):676-81.
Nichols EM, Barbour TD, Pappworth IY, Wong EK, Palmer JM, Sheerin NS, Pickering MC, Marchbank KJ. 2015. An extended mini-complement factor H molecule ameliorates
experimental C3 glomerulopathy. Kidney Int. 88(6):1314-1322.
Nilsson UR, Müller-Eberhard HJ. 1965. Isolation of beta 1F-globulin from human serum and its characterization as the fifth component of complement. J. Exp. Med. 122:277–298.
Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C. 2014.
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol. 29(5):841-51.
* Nozal P, Strobel S, Ibernon M, López D, Sánchez-Corral P, Rodríguez de Córdoba S, Józsi M, López-Trascasa M. 2012. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin Kidney J. 5(2):133-136.
* Oppermann M, Manuelian T, Józsi M, Brandt E, Jokiranta TS, Heinen S, Meri S, Skerka C, Götze O, Zipfel PF. 2006. The C-terminus of complement regulator Factor H mediates target
recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol.
144(2):342-52.
Pérez-Caballero D, González-Rubio C, Gallardo ME, Vera M, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. 2001. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet. 68(2):478-84.
Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M. 2002.
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 31(4):424-8.
Recalde S, Tortajada A, Subias M, Anter J, Blasco M, Maranta R, Coco R, Pinto S, Noris M, García-Layana A, Rodríguez de Córdoba S. 2016. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. J Am Soc Nephrol. 27(5):1305-11.
Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship TH. 2001. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet. 68(2):485-90.
Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 11(9):785-97.
Ricklin D, Lambris JD. 2013. Complement in immune and inflammatory disorders:
pathophysiological mechanisms. J Immunol. 190(8):3831-8.
Ricklin D, Reis ES, Lambris JD. 2016. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 12(7):383-401.
Ricklin D, Lambris JD. 2016. Therapeutic control of complement activation at the level of the central component C3. Immunobiology. 221(6):740-6.
Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. 2004. The human complement factor H: Functional roles, genetic variations and disease associations. Mol. Immunol. 41:355–367.
Rodríguez de Córdoba S, Goicoechea de Jorge E. 2008. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol. 151(1):1-13.
Sánchez-Corral P, Pérez-Caballero D, Huarte O, Simckes AM, Goicoechea E, López-Trascasa M, de Córdoba SR. 2002. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet. 71(6):1285-95.
Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M. 2004.
Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol.
41(1):81-4.
Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, Lyon M, Uhrín D, Barlow PN. 2008. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol. 181(4):2610-9.
Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD. 2013. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol. 190(11):5712-21.
Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A; Indian HUS Registry. 2014. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 85(5):1151-60.
Szebeni J. 2005. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 216(2-3):106-21.
Szebeni J. 2014. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 61(2):163-73.
Timmann C, Leippe M, Horstmann RD. 1991. Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory functions. J Immunol. 146(4):1265-70.
Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O, Rodríguez de Córdoba S. 2013. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest. 123(6):2434-46.
Trouw LA, Bengtsson AA, Gelderman KA, Dahlbäck B, Sturfelt G, Blom AM. 2007. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem.
282(39):28540-8.
Vik DP, Muñoz-Cánoves P, Kozono H, Martin LG, Tack BF, Chaplin DD. 1990.
Identification and sequence analysis of four complement factor H-related transcripts in mouse liver. J Biol Chem. 265(6):3193-201.
Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA. 1998. Genetic studies into inherited and sporadic hemolytic uremic syndrome.
Kidney Int. 53(4):836-44.
Weiler JM, Daha MR, Austen KF, Fearon DT. 1976. Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl. Acad. Sci. USA 73:3268–3272.
Whaley K, Ruddy S. 1976. Modulation of the alternative complement pathway by beta 1H globulin. J. Exp. Med. 144:1147–1163.
Wong EK, Anderson HE, Herbert AP, Challis RC, Brown P, Reis GS, Tellez JO, Strain L, Fluck N, Humphrey A, Macleod A, Richards A, Ahlert D, Santibanez-Koref M, Barlow PN, Marchbank KJ, Harris CL, Goodship TH, Kavanagh D. 2014. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with
membranoproliferative GN. J Am Soc Nephrol. 25(11):2425-33.
Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 10(7):728-33.
Zipfel PF, Skerka C. 1994. Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol Today. 15(3):121-6.
Zipfel PF, Skerka C. 1999. FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. Immunol Today. 20(3):135-40.
* Zipfel PF, Heinen S, Józsi M, Skerka C. 2006. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 43:97-106.
* Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C. 2007. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3(3):e41.
Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Córdoba SR, Noris M, Pickering M, Smith R. 2015. The role of complement in C3 glomerulopathy. Mol Immunol. 67(1):21-30.
Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. 2012. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 8(11):643-57.